Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease,Biochemical Relapse,and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022 |
| |
| Institution: | 1. Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland;2. Università della Svizzera Italiana, Lugano, Switzerland;3. Genitourinary Oncology, Prostate Brachytherapy Unit, Gustave Roussy, Paris, France;4. Monash University and Eastern Health, Victoria, Australia;5. The Institute of Cancer Research, London, UK;6. Royal Marsden Hospital, London, UK;7. Institut Gustave Roussy, University of Paris Saclay, Villejuif, France;8. University Jean Monnet, St Etienne, France;9. Carolina Urologic Research Center, Myrtle Beach, SC, USA;10. Urology/Surgical Oncology, GenesisCare, Myrtle Beach, SC, USA;11. UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA;12. Massachusetts General Hospital Cancer Center, Boston, MA, USA;13. Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women''s Hospital, Harvard Medical School, Boston, MA, USA;14. Cliniques universitaires Saint Luc, Brussels, Belgium;15. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA;p. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;q. Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA;r. University College London Cancer Institute, London, UK;s. Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA;t. Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA;u. Department of Urology, Skåne University Hospital, Malmö, Sweden;v. Département de Radiothérapie, Gustave Roussy, Université Paris-Saclay, Villejuif, France;w. Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy;x. Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK;y. Christie NHS Trust and CRUK Manchester Institute and Cancer Centre, Manchester, UK;z. Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon;11. Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy;22. Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain;33. Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain;44. Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA;55. BC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada;66. Guys and St Thomas''s NHS Foundation Trust, London, UK;77. Research Department of Primary Care & Population Health, Royal Free Campus, University College London, London, UK;88. The Christie and Salford Royal Hospitals, Manchester, UK;99. Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;1010. Department of Urology, Charité Universitätsmedizin, Berlin, Germany;1111. Department of Urology, Medical University of Vienna, Vienna, Austria;1212. Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Cantabria, Spain;1313. The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK;1414. Houston Methodist Cancer Center, Houston, TX, USA;1515. Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA;pp. Department of Surgery, University of Port Harcourt Teaching Hospital, Alakahia, Port Harcourt, Nigeria;qq. University of California Davis School of Medicine, Sacramento, CA, USA;rr. IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy;ss. University of California San Francisco, San Francisco, CA, USA;tt. Department of Radiation-Oncology, Ghent University Hospital, Ghent, Belgium;uu. Department of Urology, Ospedale Regionale di Lugano, Civico USI - Università della Svizzera Italiana, Lugano, Switzerland;vv. Department of Surgery, Prostate Cancer Research Program, Monash University, Melbourne, Australia;ww. Department of Anatomy & Developmental Biology, Faculty of Nursing, Medicine & Health Sciences, Monash University, Melbourne, Australia;xx. Department of Medicine, Duke Cancer Institute, Duke University, Durham, NC, USA;yy. Department of Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA;zz. Urological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada;111. Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille Université, Marseille, France;222. Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA;333. Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway;444. Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany;555. University of British Columbia, Vancouver, British Columbia, Canada;666. Prostate Cancer Theranostics and Imaging Centre of Excellence, Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia;777. Chris O''Brien Lifehouse, Camperdown, NSW, Australia;888. Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia;999. The University of Sydney, Sydney, NSW, Australia;101010. Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA;111111. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy;121212. Department of Radiotherapy, European Institute of Oncology (IEO) IRCCS, Milan, Italy;131313. School of Cancer Sciences, University of Glasgow, Glasgow, UK;141414. Division of Medical Oncology, National Cancer Centre, Singapore;151515. Faculty of Medicine and Health Technology, Tampere University and Tampere Cancer Center, Tampere, Finland;ppp. Research, Development and Innovation Center, Tampere University Hospital, Tampere, Finland;qqq. Department of Urology and the Naef K. Basile Cancer Institute (NKBCI), American University of Beirut Medical Center, Beirut, Lebanon;rrr. Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada;sss. Oncology Institute, Shamir Medical Center, Be''er Ya''akov, Israel;ttt. Faculty of Medicine, Tel-Aviv University, Israel;uuu. University of Athens Alexandra Hospital, Athens, Greece;vvv. Department of Radiation Oncology, University of Miami Sylvester Cancer Center, Miami, FL, USA;www. Beneficiência Portuguesa de São Paulo, São Paulo, SP, Brasil;xxx. Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil;yyy. Department of Medical Oncology and Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO) and Vall d’Hebron University Hospital, Barcelona, Spain;zzz. Faculty of Education, Health and Wellbeing, Walsall Campus, Walsall, UK;1111. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands;2222. Department of Urology, University Hospital Schleswig-Holstein, Luebeck, Germany;3333. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;4444. National Institute of Oncology, Mohamed V University, Rabat, Morocco;5555. Clemenceau Medical Center, Dubai, United Arab Emirates;6666. Faculty of Medicine, American University of Beirut, Beirut, Lebanon;7777. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia;8888. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;9999. Tata Memorial Centre, Mumbai, India;10101010. Department of Radiation Oncology, Brigham and Women''s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA;11111111. Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA;12121212. Department of Radiation Oncology, Iridium Netwerk, Antwerp, Belgium;13131313. Department of Human Structure and Repair, Ghent University, Ghent, Belgium;14141414. Patrick G. Johnston Centre for Cancer Research, Queen''s University Belfast, Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland;15151515. Mount Vernon Cancer Centre and Institute of Cancer Research, London, UK;pppp. Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK;qqqq. Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, Hong Kong;rrrr. The Chinese University of Hong Kong, Shatin, Hong Kong;ssss. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA;tttt. Cancer Research Chair and Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia;uuuu. Department of Urology, KFSHRC, Riyadh, Saudi Arabia;vvvv. University of California Los Angeles, Los Angeles, CA, USA;wwww. Bern Center for Precision Medicine and Department for Biomedical Research, Bern, Switzerland;xxxx. Centre Hospitalier de Université de Montréal, Montreal, Quebec, Canada;yyyy. Instituto Alexander Fleming, Buenos Aires, Argentina;zzzz. Tulane Cancer Center, New Orleans, LA, USA;11111. Department of Medicine, Weill Cornell Medical College, New York, NY, USA;22222. Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA;33333. Department of Cancer Biology, GU Malignancies Research Center, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA;44444. Rafal Masztak Grochowski Hospital, Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland;55555. Prostate Cancer Foundation, Santa Monica, CA, USA;66666. University Hospitals Seidman Cancer Center, Cleveland, OH, USA;77777. Division of Medical Oncology, Stanford University Medical Center, Stanford, CA, USA;88888. Englander Institute for Precision Medicine, Weill Cornell Medicine, Division of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Hospital, New York, NY, USA;99999. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany;1010101010. Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany;1111111111. Toho University Sakura Medical Center, Chiba, Japan;1212121212. MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK;1313131313. Department of Urology, Koc University Hospital, Istanbul, Turkey;1414141414. Department of Urology, M.A. Ayd?nlar Ac?badem University, Altunizade Hospital, Istanbul, Turkey;1515151515. Yokohama City University Medical Center, Yokohama, Japan;ppppp. Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan;qqqqq. Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey;rrrrr. Ankara University Cancer Research Institute, Ankara, Turkey;sssss. University College London, MRC Clinical Trials Unit at UCL, London, UK;ttttt. Radboud University Medical Center, Nijmegen, The Netherlands;uuuuu. Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA;vvvvv. Department of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, France;wwwww. Department of Radiation Oncology & Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL, USA;xxxxx. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China;yyyyy. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;zzzzz. Department of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA;111111. Department of Radiation Oncology, Hospital Universitario de La Princesa, Health Research Institute, Madrid, Spain;222222. Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland;333333. Faculty of Medicine, University of Geneva, Geneva, Switzerland;444444. Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Switzerland;1. Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland;2. Università della Svizzera Italiana, Lugano, Switzerland;3. Genitourinary Oncology, Prostate Brachytherapy Unit, Gustave Roussy, Paris, France;4. Monash University and Eastern Health, Victoria, Australia;5. The Institute of Cancer Research, London, UK;6. Royal Marsden Hospital, London, UK;7. Institut Gustave Roussy, University of Paris Saclay, Villejuif, France;8. University Jean Monnet, St Etienne, France;9. Carolina Urologic Research Center, Myrtle Beach, SC, USA;10. Urology/Surgical Oncology, GenesisCare, Myrtle Beach, SC, USA;11. UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA;12. Massachusetts General Hospital Cancer Center, Boston, MA, USA;13. Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women''s Hospital, Harvard Medical School, Boston, MA, USA;14. Cliniques universitaires Saint Luc, Brussels, Belgium;15. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA;p. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;q. Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA;r. University College London Cancer Institute, London, UK;s. Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA;t. Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA;u. Department of Urology, Skåne University Hospital, Malmö, Sweden;v. Département de Radiothérapie, Gustave Roussy, Université Paris-Saclay, Villejuif, France;w. Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy;x. Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK;y. Christie NHS Trust and CRUK Manchester Institute and Cancer Centre, Manchester, UK;z. Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon;11. Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy;22. Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain;33. Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain;44. Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA;55. BC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada;66. Guys and St Thomas''s NHS Foundation Trust, London, UK;77. Research Department of Primary Care & Population Health, Royal Free Campus, University College London, London, UK;88. The Christie and Salford Royal Hospitals, Manchester, UK;99. Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;1010. Department of Urology, Charité Universitätsmedizin, Berlin, Germany;1111. Department of Urology, Medical University of Vienna, Vienna, Austria;1212. Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Cantabria, Spain;1313. The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK;1414. Houston Methodist Cancer Center, Houston, TX, USA;1515. Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA;pp. Department of Surgery, University of Port Harcourt Teaching Hospital, Alakahia, Port Harcourt, Nigeria;qq. University of California Davis School of Medicine, Sacramento, CA, USA;rr. IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy;ss. University of California San Francisco, San Francisco, CA, USA;tt. Department of Radiation-Oncology, Ghent University Hospital, Ghent, Belgium;uu. Department of Urology, Ospedale Regionale di Lugano, Civico USI - Università della Svizzera Italiana, Lugano, Switzerland;vv. Department of Surgery, Prostate Cancer Research Program, Monash University, Melbourne, Australia;ww. Department of Anatomy & Developmental Biology, Faculty of Nursing, Medicine & Health Sciences, Monash University, Melbourne, Australia;xx. Department of Medicine, Duke Cancer Institute, Duke University, Durham, NC, USA;yy. Department of Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA;zz. Urological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada;111. Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille Université, Marseille, France;222. Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA;333. Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway;444. Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany;555. University of British Columbia, Vancouver, British Columbia, Canada;666. Prostate Cancer Theranostics and Imaging Centre of Excellence, Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia;777. Chris O''Brien Lifehouse, Camperdown, NSW, Australia;888. Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia;999. The University of Sydney, Sydney, NSW, Australia;101010. Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA;111111. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy;121212. Department of Radiotherapy, European Institute of Oncology (IEO) IRCCS, Milan, Italy;131313. School of Cancer Sciences, University of Glasgow, Glasgow, UK;141414. Division of Medical Oncology, National Cancer Centre, Singapore;151515. Faculty of Medicine and Health Technology, Tampere University and Tampere Cancer Center, Tampere, Finland;ppp. Research, Development and Innovation Center, Tampere University Hospital, Tampere, Finland;qqq. Department of Urology and the Naef K. Basile Cancer Institute (NKBCI), American University of Beirut Medical Center, Beirut, Lebanon;rrr. Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada;sss. Oncology Institute, Shamir Medical Center, Be''er Ya''akov, Israel;ttt. Faculty of Medicine, Tel-Aviv University, Israel;uuu. University of Athens Alexandra Hospital, Athens, Greece;vvv. Department of Radiation Oncology, University of Miami Sylvester Cancer Center, Miami, FL, USA;www. Beneficiência Portuguesa de São Paulo, São Paulo, SP, Brasil;xxx. Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil;yyy. Department of Medical Oncology and Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO) and Vall d’Hebron University Hospital, Barcelona, Spain;zzz. Faculty of Education, Health and Wellbeing, Walsall Campus, Walsall, UK;1111. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands;2222. Department of Urology, University Hospital Schleswig-Holstein, Luebeck, Germany;3333. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;4444. National Institute of Oncology, Mohamed V University, Rabat, Morocco;5555. Clemenceau Medical Center, Dubai, United Arab Emirates;6666. Faculty of Medicine, American University of Beirut, Beirut, Lebanon;7777. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia;8888. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;9999. Tata Memorial Centre, Mumbai, India;10101010. Department of Radiation Oncology, Brigham and Women''s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA;11111111. Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA;12121212. Department of Radiation Oncology, Iridium Netwerk, Antwerp, Belgium;13131313. Department of Human Structure and Repair, Ghent University, Ghent, Belgium;14141414. Patrick G. Johnston Centre for Cancer Research, Queen''s University Belfast, Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland;15151515. Mount Vernon Cancer Centre and Institute of Cancer Research, London, UK;pppp. Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK;qqqq. Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, Hong Kong;rrrr. The Chinese University of Hong Kong, Shatin, Hong Kong;ssss. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA;tttt. Cancer Research Chair and Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia;uuuu. Department of Urology, KFSHRC, Riyadh, Saudi Arabia;vvvv. University of California Los Angeles, Los Angeles, CA, USA;wwww. Bern Center for Precision Medicine and Department for Biomedical Research, Bern, Switzerland;xxxx. Centre Hospitalier de Université de Montréal, Montreal, Quebec, Canada;yyyy. Instituto Alexander Fleming, Buenos Aires, Argentina;zzzz. Tulane Cancer Center, New Orleans, LA, USA;11111. Department of Medicine, Weill Cornell Medical College, New York, NY, USA;22222. Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA;33333. Department of Cancer Biology, GU Malignancies Research Center, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA;44444. Rafal Masztak Grochowski Hospital, Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland;55555. Prostate Cancer Foundation, Santa Monica, CA, USA;66666. University Hospitals Seidman Cancer Center, Cleveland, OH, USA;77777. Division of Medical Oncology, Stanford University Medical Center, Stanford, CA, USA;88888. Englander Institute for Precision Medicine, Weill Cornell Medicine, Division of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Hospital, New York, NY, USA;99999. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany;1010101010. Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany;1111111111. Toho University Sakura Medical Center, Chiba, Japan;1212121212. MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK;1313131313. Department of Urology, Koc University Hospital, Istanbul, Turkey;1414141414. Department of Urology, M.A. Ayd?nlar Ac?badem University, Altunizade Hospital, Istanbul, Turkey;1515151515. Yokohama City University Medical Center, Yokohama, Japan;ppppp. Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan;qqqqq. Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey;rrrrr. Ankara University Cancer Research Institute, Ankara, Turkey;sssss. University College London, MRC Clinical Trials Unit at UCL, London, UK;ttttt. Radboud University Medical Center, Nijmegen, The Netherlands;uuuuu. Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA;vvvvv. Department of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, France;wwwww. Department of Radiation Oncology & Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL, USA;xxxxx. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China;yyyyy. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;zzzzz. Department of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA;111111. Department of Radiation Oncology, Hospital Universitario de La Princesa, Health Research Institute, Madrid, Spain;222222. Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland;333333. Faculty of Medicine, University of Geneva, Geneva, Switzerland;444444. Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Switzerland |
| |
| Abstract: | BackgroundInnovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management.ObjectiveTo present consensus voting results for select questions from APCCC 2022.Design, setting, and participantsBefore the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members (“panellists”) who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1–3.Outcome measurements and statistical analysisConsensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement.Results and limitationsThe voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis.ConclusionsThese voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers prioritise areas for future research. Diagnostic and treatment decisions should always be individualised based on patient and cancer characteristics (disease extent and location, treatment history, comorbidities, and patient preferences) and should incorporate current and emerging clinical evidence, therapeutic guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2022 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.Patient summaryThe Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with health care providers and patients worldwide. At each APCCC, a panel of physician experts vote in response to multiple-choice questions about their clinical opinions and approaches to managing advanced prostate cancer. This report presents voting results for the subset of questions pertaining to intermediate- and high-risk and locally advanced prostate cancer, biochemical relapse after definitive treatment, advanced (next-generation) imaging, and management of side effects caused by hormonal therapies. The results provide a practical guide to help clinicians and patients discuss treatment options as part of shared multidisciplinary decision-making. The findings may be especially useful when there is little or no high-level evidence to guide treatment decisions. |
| |
| Keywords: | Prostate cancer Locally advanced prostate cancer Biochemical recurrence Side effects Hormonal treatment Next-generation imaging Prostate-specific membrane antigen positron emission tomography imaging Adjuvant therapy Salvage therapy Salvage radiation therapy |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
